Cabaletta Bio (CABA) Research & Development (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Research & Development of $140.8 million for Q4 2025, up 512.15% year-over-year from $23.0 million in Q4 2024, and up 24258.82% quarter-over-quarter from $578000.0 in Q3 2025.
Cabaletta Bio (CABA) Research & Development (2018 - 2026) Analysis & Trends
Cabaletta Bio's Research & Development history runs 8 years deep, the most recent figure standing at $140.8 million for Q4 2025.
- In Q4 2025, Research & Development rose 512.15% year-over-year to $140.8 million; the TTM figure through Dec 2025 stood at $179.6 million (up 145.67% YoY), while the FY2025 annual figure was $142.7 million, up 46.78% from the prior year.
- Research & Development for Q4 2025 stood at $140.8 million, up from $578000.0 in the prior quarter.
- The five-year high for Research & Development was $140.8 million in Q4 2025, with the low at -$36.6 million in Q4 2023.
- The 5-year median for Research & Development is $9.7 million (2021), against an average of $16.3 million.
- The sharpest annual moves came in 2023 and 2025: Research & Development slumped 395.48% in 2023, then surged 512.15% in 2025.
- Cabaletta Bio's Research & Development stood at $9.9 million in 2021, then increased by 25.01% to $12.4 million in 2022, then tumbled by 395.48% to -$36.6 million in 2023, then surged by 162.77% to $23.0 million in 2024, then soared by 512.15% to $140.8 million in 2025.
- Business Quant data shows CABA's Research & Development at $140.8 million in Q4 2025, $578000.0 in Q3 2025, and $37.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | 44.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.43 Mn |
| Dec 31, 2025 | 140.79 Mn |
| Sep 30, 2025 | 578,000.00 |
| Jun 30, 2025 | 37.64 Mn |
| Mar 31, 2025 | 543,000.00 |
| Dec 31, 2024 | 23.00 Mn |
| Sep 30, 2024 | 26.29 Mn |
| Jun 30, 2024 | 23.43 Mn |
| Mar 31, 2024 | 369,000.00 |
| Dec 31, 2023 | -36.64 Mn |
| Sep 30, 2023 | 13.79 Mn |
| Jun 30, 2023 | 11.80 Mn |
| Mar 31, 2023 | 12.44 Mn |
| Dec 31, 2022 | 12.40 Mn |
| Sep 30, 2022 | 8.22 Mn |
| Jun 30, 2022 | 9.51 Mn |
| Mar 31, 2022 | 9.17 Mn |
| Dec 31, 2021 | 9.92 Mn |
| Sep 30, 2021 | 8.17 Mn |
| Jun 30, 2021 | 7.85 Mn |